Experimental justification of the possibility of creating the new metabolic drug

Publication type Article
Status Published
Affiliation: Federal State Budgetary Scientifi c Institution Research Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Affiliation: Federal State Budgetary Scientifi c Institution Research Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Journal nameRossiiskii immunologicheskii zhurnal
EditionVolume 12 Issue 3

This scientifi c work is devoted to the study of the possibility of creating a new metabolic drug (using biologically active substances of the probiotic strain Bacillus subtilis B-3679) for use as a preventive and therapeutic agent for infl ammatory diseases of tissues and organs of the oral cavity. Previously, the metabolites of spore probiotic microorganisms were practically not used for the design of medical pharmacological preparations.

Keywordsprobiotic microorganisms, metabiotic, experimental study
AcknowledgmentThe work was performed as part of the state assignment of the IIB UB RAS (R & D Number No. AAAA-A18–118020690020–1).
Publication date12.01.2019
Cite   Download pdf To download PDF you should sign in
Размещенный ниже текст является ознакомительной версией и может не соответствовать печатной

views: 1112

Readers community rating: votes 0

1. Zabokritskij N. A. Ehksperimental'naya otsenka korrektsii gumoral'nogo immuniteta gepatoprotektornym preparatom gepatobiol u laboratornykh zhivotnykh s ostrym toksicheskim gepatitom. Rossijskij immunologicheskij zhurnal, 2017, 11, 2(20), 123–126. [Zabokritskiy N. A. Experimental estimation of correction of humoral immunity hepatoprotective drug hepatobiol in laboratory animals C acute toxic hepatitis, 2017, 11, 2(20), 123–126].

2. Zabokritskij N. A. Otsenka immunotropnogo dejstviya probiotika batsilakt v sostave transdermal'nykh terapevticheskikh sistem. Rossijskij immunologicheskij zhurnal, 2017, 11, 2(20), 126–129. [Zabokritskiy N. A. Preclinical evaluation of immunotropic action of probiotics bacilack transdermal therapeutic system, 2017, 11, 2(20), 126–129].

3. Zabokritskij N. A. Obosnovanie napravlenij v razrabotke i ehksperimental'nom izuchenii novykh farmakologicheskikh preparatov na osnove probiotikov i ikh biologicheski aktivnykh produktov: avtoref. dis. … d-ra. med. nauk., 2014. 3–16. [Zabokritskiy N. A. Study areas in the development and experimental study of new pharmacological products based on probiotics and their bioactive products: abstract of dis. … dr. med. sciences, 2014. 3–16].

4. Labinskaya A. S. Mikrobiologiya s tekhnikoj mikrobiologicheskikh issledovanij. Binom, M., 2012. 72–124. [Labinskaya A. S. Microbiology with technique of microbiological studies.: Binom, Moscow, 2012. 72–124].

5. Holzapfel W. H., Schillinger U. Introduction to preand probiotics. Food Research International 35, 2002, 109–116.

6. Kailasapathy K. A., Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifi dobacterium spp. Immunol. Cell. Biol., 2000, 78, 80–88.

7. Lee Y. K., Salminen S. Handbook of Probiotics and Prebiotics. John Wiley and Sons, Ltd., 2009, 132–144.

8. Russel J., Cohn R.,Probiotics. U.K., Edinburgh: LENNEX Corp. 2012, 5–58.

Система Orphus